
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025

Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025
Hemostemix talks work in Florida
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
Pharmadrug firms up deal to acquire 40% of Canurta
Glass House Brands to release Q3 results Nov. 12
Knight Therapeutics Announces Launch of JORNAY PM(TM) in Canada
BIOVAXYS ANNOUNCES UPSIZING OF LIFE OFFERING OF UP TO $2M
Knight launches Minjuvi in Argentina for DLBCL patients
Hemostemix's Boots on the Ground in Florida October Update
Bionxt receives EAPO readiness-to-grant notification
PharmaDrug Signs Definitive Agreement to Acquire Equity Interest in Canurta Inc
OrganOx Completes Acquisition by Terumo Corporation to Advance the Future of Organ Transplantation
Glass House Brands to Host Third Quarter 2025 Earnings Call on November 12, 2025
PreveCeutical Closes Second Tranche of Non-Brokered Private Placement
BioNxt Reports "Readiness to Grant" Patent Notification from the Eurasian Patent Organization